(CYRX) Cryoport - Ratings and Ratios
Cryogenic Freezers, Cryogenic Dewars, Accessories, Shipping Systems, Biostorage
CYRX EPS (Earnings per Share)
CYRX Revenue
Description: CYRX Cryoport
Company Overview
Cryoport Inc a leading provider of temperature-controlled supply chain solutions in the biopharma/pharma, health, and medicine markets. The expertise lies in providing cryogenic logistics and biostorage services.
The company operates through two main segments segments: Life Sciences Services and Life Sciences Sciences Products. The revenue is generated through a mix of service offerings and product sales, catering to the life sciences industry.
Notably, Cryoport has established itself as a a major player in the biopharmaceutical logistics space, with a strong presence in the the US market. The companys has shown significant growth, driven by increasing demand for temperature-controlled logistics and biostorage services.
Key Performance Indicators (KPIs) such as Revenue Growth Rate, Customer Acquisition Cost,, and Customer Retention Rate are crucial in evaluating the companys performance business performance. Additionally, metrics like the Gross Margin and Operating Expenses as a Percentage of Revenue provide insights into the operational the efficiency.
With a Market Capitalization of $366. With a forward P/E ratio of 58 58.14, the stock is trading at a premium, indicating high growth expectations.
The information provided offers a comprehensive overview of the the companys business model, market presence, and financial performance. The analysis highlights the importance of temperature-controlled logistics and biostorage services in the life sciences sciences industry and Cryoports a major player in this this space. The key takeaway is that Cryoport is well-positioned for for future growth, driven by increasing demand for its its services and products. in the biopharmaceutical logistics industry.Additional Sources for CYRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
CYRX Stock Overview
| Market Cap in USD | 367m |
| Sector | Industrials |
| Industry | Integrated Freight & Logistics |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception | 2005-03-15 |
CYRX Stock Ratings
| Growth Rating | -82.7 |
| Fundamental | -61.2 |
| Dividend Rating | 0.0 |
| Rel. Strength | -18.9 |
| Analysts | 4 of 5 |
| Fair Price Momentum | 6.04 USD |
| Fair Price DCF | - |
CYRX Dividends
Currently no dividends paidCYRX Growth Ratios
| Growth Correlation 3m | 82.5% |
| Growth Correlation 12m | -69.2% |
| Growth Correlation 5y | -92.9% |
| CAGR 5y | -26.44% |
| CAGR/Max DD 5y | -0.28 |
| Sharpe Ratio 12m | -0.66 |
| Alpha | -10.98 |
| Beta | 0.681 |
| Volatility | 69.84% |
| Current Volume | 460.6k |
| Average Volume 20d | 466.6k |
| Stop Loss | 6.9 (-5.9%) |
As of July 16, 2025, the stock is trading at USD 7.33 with a total of 460,630 shares traded.
Over the past week, the price has changed by -3.55%, over one month by +5.77%, over three months by +30.43% and over the past year by -1.35%.
No, based on ValueRay´s Fundamental Analyses, Cryoport (NASDAQ:CYRX) is currently (July 2025) a stock to sell. It has a ValueRay Fundamental Rating of -61.24 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CYRX is around 6.04 USD . This means that CYRX is currently overvalued and has a potential downside of -17.6%.
Cryoport has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CYRX.
- Strong Buy: 4
- Buy: 2
- Hold: 4
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, CYRX Cryoport will be worth about 6.6 in July 2026. The stock is currently trading at 7.33. This means that the stock has a potential downside of -9.82%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.9 | 49.1% |
| Analysts Target Price | 10.9 | 49.2% |
| ValueRay Target Price | 6.6 | -9.8% |